News

Yahoo Finance1y
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
SANTYL is currently the market-leading enzymatic debridement product, with more than $360 million in estimated annual sales in the United States. Results from the previously disclosed Phase II ...
Yahoo Finance19d
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
“These new findings are consistent with my prior experience using EscharEx in clinical trials and SANTYL in clinical practice,” said Dr. Cyaandi Dove, DPM, of the University of Texas Health ...
Houston Chronicle19y
(PRN) HEALTHPOINT to Begin Marketing and Selling Collagenase SANTYL (R)
FORT WORTH, Texas, April 4 /PRNewswire/-- HEALTHPOINT, Ltd., a DFB Pharmaceuticals Inc. affiliate company, today announced that it will begin marketing and selling the Collagenase SANTYL(R ...
Nasdaq19d
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers
Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®’s superior clinical performance and comparable safety profile to SANTYL® “These new findings are ...